The Drug Enforcement Administration today issued its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. The proposed rule will be published in the Aug. 20 Federal Register with comments accepted for 30 days. AHA and others have urged DEA to include drug shortages as a factor when setting and adjusting aggregate and individual manufacturers’ production quotas for controlled substances.
 

Related News Articles

Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…
Headline
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its…
Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
The House Energy and Commerce Committee held a hearing on legislative proposals to prevent and respond to generic drug shortages. In comments submitted…
Headline
AHA recently voiced support for four bipartisan bills introduced in the Senate to help alleviate the nation’s chronic and growing drug shortages.   …